These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

897 related items for PubMed ID: 12466317

  • 1. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R, Tonolo G.
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [Abstract] [Full Text] [Related]

  • 2. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers.
    Deferrari G, Ravera M, Deferrari L, Vettoretti S, Ratto E, Parodi D.
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S224-9. PubMed ID: 12466318
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. What have we learned from the current trials?
    Abbott KC, Bakris GL.
    Med Clin North Am; 2004 Jan; 88(1):189-207. PubMed ID: 14871059
    [Abstract] [Full Text] [Related]

  • 5. Renal protection and antihypertensive drugs: current status.
    Salvetti A, Mattei P, Sudano I.
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR.
    Drugs; 2005 May; 65 Suppl 2():29-39. PubMed ID: 16398060
    [Abstract] [Full Text] [Related]

  • 9. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A, Peeters P, Vanholder R.
    Acta Clin Belg; 2004 May; 59(1):44-56. PubMed ID: 15065696
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 May; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M, Deferrari L, Ratto E, Vettoretti S, Parodi D, Deferrari G.
    Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C.
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.